Unternehmens-Profil
Sanofi SA is a French multinational pharmaceutical and healthcare company headquartered in Paris, renowned for its research, development, manufacturing, and marketing of innovative medicines and vaccines. Established in 1973, it has evolved through key mergers, including with Synthélabo in 1999 and Aventis in 2004, forming a global leader with over 90,000 employees across 90 countries. Sanofi focuses on seven major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines, positioning it as the world's largest vaccine producer via its Sanofi Pasteur subsidiary. Its portfolio spans prescription drugs like Dupixent for eczema and autoimmune conditions, Lovenox for thrombosis, Taxotere for cancer, and treatments for rare diseases such as Gaucher's and hemophilia. Sanofi also offers over-the-counter products including Allegra and IcyHot. As an R&D-driven, AI-powered biopharma entity, it invests heavily in immunology, neurology, diabetes innovation, and mRNA technologies, maintaining a robust pipeline of 80 compounds in clinical development across five therapeutic areas to address unmet medical needs and advance public health worldwide.
Bewertungs-Kennzahlen
Allgemeine Finanzkennzahlen
Chart · 90 Tage
Letzter Kurs: 73,74 EUR· Stand 07.05.2026
News · Sanofi
- 70 May Graham Value All-Stars ('GVAS'): 13 To Buy
- Santander plans to retire TSB brand, FT reports
- Spanish bank Sabadell sells TSB to Banco Santander for 3.3 billion euros
- Santander completes £2.65B takeover of TSB
- Webster Financial Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Webster Financial Corporation - WBS